Plain-English translation of NCT07730021 on ClinicalTrials.gov ↗ · Source last updated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
United States
Japan
Phase
Safety & dosing / Early efficacy
Sponsor
Astellas Pharma Global Development, Inc.
Enrollment target
~392 participants
Started
September 2026
Primary completion
February 2030
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Astellas Pharma Global Development, Inc.
Astellas Pharma Global Development, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.